Subject: To understand the role of drospirenone-ethinylestradiol combination, used as oral contraceptive, in polycystic ovarian syndrome and dysmenorrhea in real-life clinical practice.
Oral contraceptive pills (OCPs) have been the first‑line therapy for concurrent treatment of menstrual irregularity, acne, and hirsutism in women with polycystic ovarian syndrome (PCOS), thus playing an important role in the symptom management of the PCOS women. The Combined OCP (COC) also improve dysmenorrhea and menorrhagia, treat premenstrual syndrome, prevent menstrual migraines, treat pelvic pain related to endometriosis, and decrease the risk of endometrial and ovarian cancer. Though weight reduction, exercise, and lifestyle modification are the first line of management with beneficial effects, especially in the obese PCOS women, COC have been recommended to improve the clinical manifestations.
Dysmenorrhea refers to painful uterine cramps that occur during menstruation, concentrated in the lower abdomen, and may be accompanied by backache or other discomforts. It can be classified into primary dysmenorrhea (painful menstruation in the absence of pelvic pathology) and secondary dysmenorrhea (painful menses due to pelvic pathology or a recognized medical condition, such as endometriosis, adenomyosis, or pelvic inflammation) based on pathophysiology. Combined oral contraceptives have been used in the treatment of dysmenorrhea since their introduction for general use in 1960. The mechanism of action of COCs is to inhibit ovulation by estrogen and progesterone, thereby inhibiting the synthesis of prostaglandin. Drospirenone and ethinylestradiol is a new generation of COC which combines progestogenic, antimineralocorticoid, and antiandrogenic effects and does not exhibit any estrogenic, androgenic, or glucocorticoid effects, providing non-contraceptive benefits.
We have planned this survey to understand the role of drospirenone-ethinylestradiol combination, used as oral contraceptive, in polycystic ovarian syndrome and dysmenorrhea in real-life clinical practice.
We invite you to participate in this survey by responding to the survey questions and sharing your opinion on the role of drospirenone-ethinylestradiol combination, used as oral contraceptive, in polycystic ovarian syndrome and dysmenorrhea in your routine clinical practice.
We trust you and we are partners in ensuring safe and effective drug therapy. In that spirit we hope you will consent to participate in this survey.
|
}}){kind=logo}
}})